Cargando…

Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia

SIMPLE SUMMARY: Acute myeloid leukemia (AML) is an aggressive form of cancer found in the blood and bone marrow with poor survival rates. Patients with AML are known to have many defects in their immune system which render immune cells unable to detect and/or kill cancer cells. Natural Killer (NK) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lordo, Matthew R., Scoville, Steven D., Goel, Akul, Yu, Jianhua, Freud, Aharon G., Caligiuri, Michael A., Mundy-Bosse, Bethany L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830843/
https://www.ncbi.nlm.nih.gov/pubmed/33477248
http://dx.doi.org/10.3390/cancers13020320
_version_ 1783641505242546176
author Lordo, Matthew R.
Scoville, Steven D.
Goel, Akul
Yu, Jianhua
Freud, Aharon G.
Caligiuri, Michael A.
Mundy-Bosse, Bethany L.
author_facet Lordo, Matthew R.
Scoville, Steven D.
Goel, Akul
Yu, Jianhua
Freud, Aharon G.
Caligiuri, Michael A.
Mundy-Bosse, Bethany L.
author_sort Lordo, Matthew R.
collection PubMed
description SIMPLE SUMMARY: Acute myeloid leukemia (AML) is an aggressive form of cancer found in the blood and bone marrow with poor survival rates. Patients with AML are known to have many defects in their immune system which render immune cells unable to detect and/or kill cancer cells. Natural Killer (NK) cells are innate immune effector cells responsible for surveying the body to eliminate cancer cells as well as alert other immune cells to help clear the cancer cells. NK cells have developmental and functional defects in AML patients. While advances have been made to understand these NK cell defects in the setting of AML, the role of other closely related and recently discovered members of the innate lymphoid cell (ILC) family is much less clear. The ILC family is comprised of NK cells, ILC1s, ILC2s, and ILC3s, and due in part to their recent discovery, non-NK ILCs are just now beginning to be investigated in the setting of AML. By better understanding how AML alters the normal function of these cell types, and how the alteration regulates AML growth, we may be able to target and tailor new forms of therapy for patients. ABSTRACT: Over the past 50 years, few therapeutic advances have been made in treating acute myeloid leukemia (AML), an aggressive form of blood cancer, despite vast improvements in our ability to classify the disease. Emerging evidence suggests the immune system is important in controlling AML progression and in determining prognosis. Natural killer (NK) cells are important cytotoxic effector cells of the innate lymphoid cell (ILC) family that have been shown to have potent anti-leukemic functions. Recent studies are now revealing impairment or dysregulation of other ILCs in various types of cancers, including AML, which limits the effectiveness of NK cells in controlling cancer progression. NK cell development and function are inhibited in AML patients, which results in worse clinical outcomes; however, the specific roles of other ILC populations in AML are just now beginning to be unraveled. In this review, we summarize what is known about the role of ILC populations in AML.
format Online
Article
Text
id pubmed-7830843
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78308432021-01-26 Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia Lordo, Matthew R. Scoville, Steven D. Goel, Akul Yu, Jianhua Freud, Aharon G. Caligiuri, Michael A. Mundy-Bosse, Bethany L. Cancers (Basel) Review SIMPLE SUMMARY: Acute myeloid leukemia (AML) is an aggressive form of cancer found in the blood and bone marrow with poor survival rates. Patients with AML are known to have many defects in their immune system which render immune cells unable to detect and/or kill cancer cells. Natural Killer (NK) cells are innate immune effector cells responsible for surveying the body to eliminate cancer cells as well as alert other immune cells to help clear the cancer cells. NK cells have developmental and functional defects in AML patients. While advances have been made to understand these NK cell defects in the setting of AML, the role of other closely related and recently discovered members of the innate lymphoid cell (ILC) family is much less clear. The ILC family is comprised of NK cells, ILC1s, ILC2s, and ILC3s, and due in part to their recent discovery, non-NK ILCs are just now beginning to be investigated in the setting of AML. By better understanding how AML alters the normal function of these cell types, and how the alteration regulates AML growth, we may be able to target and tailor new forms of therapy for patients. ABSTRACT: Over the past 50 years, few therapeutic advances have been made in treating acute myeloid leukemia (AML), an aggressive form of blood cancer, despite vast improvements in our ability to classify the disease. Emerging evidence suggests the immune system is important in controlling AML progression and in determining prognosis. Natural killer (NK) cells are important cytotoxic effector cells of the innate lymphoid cell (ILC) family that have been shown to have potent anti-leukemic functions. Recent studies are now revealing impairment or dysregulation of other ILCs in various types of cancers, including AML, which limits the effectiveness of NK cells in controlling cancer progression. NK cell development and function are inhibited in AML patients, which results in worse clinical outcomes; however, the specific roles of other ILC populations in AML are just now beginning to be unraveled. In this review, we summarize what is known about the role of ILC populations in AML. MDPI 2021-01-17 /pmc/articles/PMC7830843/ /pubmed/33477248 http://dx.doi.org/10.3390/cancers13020320 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lordo, Matthew R.
Scoville, Steven D.
Goel, Akul
Yu, Jianhua
Freud, Aharon G.
Caligiuri, Michael A.
Mundy-Bosse, Bethany L.
Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia
title Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia
title_full Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia
title_fullStr Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia
title_full_unstemmed Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia
title_short Unraveling the Role of Innate Lymphoid Cells in Acute Myeloid Leukemia
title_sort unraveling the role of innate lymphoid cells in acute myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830843/
https://www.ncbi.nlm.nih.gov/pubmed/33477248
http://dx.doi.org/10.3390/cancers13020320
work_keys_str_mv AT lordomatthewr unravelingtheroleofinnatelymphoidcellsinacutemyeloidleukemia
AT scovillestevend unravelingtheroleofinnatelymphoidcellsinacutemyeloidleukemia
AT goelakul unravelingtheroleofinnatelymphoidcellsinacutemyeloidleukemia
AT yujianhua unravelingtheroleofinnatelymphoidcellsinacutemyeloidleukemia
AT freudaharong unravelingtheroleofinnatelymphoidcellsinacutemyeloidleukemia
AT caligiurimichaela unravelingtheroleofinnatelymphoidcellsinacutemyeloidleukemia
AT mundybossebethanyl unravelingtheroleofinnatelymphoidcellsinacutemyeloidleukemia